Existing Compounds Can Target KCC2 Protein to Ease Rett Symptoms, Early Study Reports
Several compounds already approved by the U.S. Food and Drug Administration (FDA) can increase the expression of the KCC2 protein in nerve cells, easing motor and respiratory symptoms in a mouse model of Rett syndrome. The study, “Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects…